Updated Jul 16, 2026
Aftab Dana has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $9.08M.
Dana Aftab is an executive at Exelixis, Inc., where she has held various roles including EVP of Research and Development and Chief Scientific Officer. She is involved in the development of cancer treatments, contributing to the company's focus on innovative therapies for oncology.
| Role | EVP, Research and Development |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-28 | EXEL | EXELIXIS, INC. | S — Open-market sale | 43.5K | $50.35 | $2.19M |
| 2026-05-19 | EXEL | EXELIXIS, INC. | F — Tax withholding / forfeiture | 30.6K | $51.10 | $1.56M |
| 2026-03-03 | EXEL | EXELIXIS, INC. | A — Grant or award | 52.0K | $0.00 | |
| 2026-02-26 | EXEL | EXELIXIS, INC. | S — Open-market sale | 47.9K | $44.50 | $2.13M |
| 2026-02-23 | EXEL | EXELIXIS, INC. | S — Open-market sale | 29.9K | $44.35 | $1.32M |
| 2026-02-19 | EXEL | EXELIXIS, INC. | F — Tax withholding / forfeiture | 12.7K | $43.92 | $559K |
| 2026-02-19 | EXEL | EXELIXIS, INC. | F — Tax withholding / forfeiture | 26.5K | $43.92 | $1.16M |
| 2026-01-17 | EXEL | EXELIXIS, INC. | F — Tax withholding / forfeiture | 27.3K | $45.23 | $1.23M |
| 2026-01-17 | EXEL | EXELIXIS, INC. | A — Grant or award | 119.6K | $0.00 | |
| 2025-10-08 | EXEL | EXELIXIS, INC. | A — Grant or award | 50.7K | $0.00 | |
| 2024-11-19 | EXEL | EXELIXIS, INC. | F — Tax withholding / forfeiture | 12.8K | $35.05 | $450K |
| 2024-11-07 | EXEL | EXELIXIS, INC. | S — Open-market sale [10b5-1] | 97.0K | $35.00 | $3.39M |
| 2024-11-07 | EXEL | EXELIXIS, INC. | M — Option exercise [10b5-1] | 97.0K | $18.80 | $1.82M |
| 2024-11-01 | EXEL | EXELIXIS, INC. | S — Open-market sale [10b5-1] | 1.2K | $31.40 | $36K |
Dana Aftab is an executive at Exelixis, Inc., where she has held various roles including EVP of Research and Development and Chief Scientific Officer. She is involved in the development of cancer treatments, contributing to the company's focus on innovative therapies for oncology.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($9.08M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Aftab Dana profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.